Cancer during pregnancy: perinatal outcome after in utero exposure to chemotherapy.

Autor: Abdel-Hady el-S; Department of Obstetrics and Gynecology, Mansoura University, Mansoura, Egypt. elsaidhady@yahoo.co.uk, Hemida RA, Gamal A, El-Zafarany M, Toson E, El-Bayoumi MA
Jazyk: angličtina
Zdroj: Archives of gynecology and obstetrics [Arch Gynecol Obstet] 2012 Aug; Vol. 286 (2), pp. 283-6. Date of Electronic Publication: 2012 Mar 13.
DOI: 10.1007/s00404-012-2287-5
Abstrakt: Objectives: To study the outcome of pregnancies complicated by malignant disease, in particular neonatal morbidity and mortality after in utero exposure to chemotherapy.
Methods: This prospective study included 118 patients diagnosed with malignant disease for the first time during pregnancy over an 8-year period (March 2003-March 2011). Outcome of neonates born to mothers who received chemotherapy during pregnancy was studied and compared with a control group.
Results: The commonest cancer type diagnosed during pregnancy (56/118 = 47.45 %) was breast carcinoma followed by lymphoma/leukemia (32 = 27.12 %). Gynecological tumors (all ovarian) represented 10.16 %, soft tissue tumors 5.08 %, colorectal 4.23 %, thyroid 2.54 % and others 3.38 %. Sixty-one (51.64 %) women received chemotherapy (average 3 ± 2 cycles) during the second and third trimesters. The incidence of neonatal survival, preterm birth, small for gestational age and congenital malformations was not significantly different between women who received chemotherapy during pregnancy and the control group. Five (4.23 %) women with advanced disease died during or shortly after termination of pregnancy.
Conclusion: In utero exposure to chemotherapy during the second and third trimesters of pregnancy carries minimal morbidity to the unborn fetus.
Databáze: MEDLINE
Externí odkaz: